November 10, 2026

Third Quarter 2026 Financial Results & Corporate Update

This presentation is for investor relations purposes only - Not for product promotional purposes

Agenda

1. Opening Remarks
2. Q3 2026 Highlights & Recent Accomplishments
3. Pipeline
4. CARVYKTI® Performance Overview
5. Financial Performance
6. Q&A

This presentation is for investor relations purposes only - Not for product promotional purposes



Ingrid Zhang
Chief Executive Officer



Alan Bash
President, CARVYKTI®



Carlos Santos
Chief Financial Officer

This presentation is for investor relations purposes only - not for product promotional purposes

Forward-looking Statements

This presentation has been prepared by Legend Biotech Corporation ("Legend Biotech" or the "Company") solely for information purpose and does not contain all relevant information relating to the Company.

The safety and efficacy of the agents and/or uses under investigation discussed in this presentation have not been established, except to the extent specifically provided by marketing authorizations previously received from relevant health authorities. Further, for investigational agents and/or uses, the Company cannot guarantee health authority approval or that such agents and/or uses will become commercially available in any country.

Certain information contained in this presentation and statements made orally during this presentation relate to or are based on studies, publications, surveys and other data obtained from third-party sources and Legend Biotech's own internal estimates and research. While Legend Biotech believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. While Legend Biotech believes its internal research is reliable, such research has not been verified by any independent source.

Statements in this presentation about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, constitute "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995.

These statements include, but are not limited to, statements relating to Legend Biotech's strategies and objectives; statements relating to CARVYKTI® (ciltacabtagene autoleucel; cilta-cel), including patient population of CARVYKTI®, Legend Biotech's expectations for CARVYKTI®, including manufacturing expectations for CARVYKTI®; and statements about regulatory submissions for CARVYKTI®, statements related to Legend Biotech's ability to achieve operating profit; statements related to Legend Biotech's ability to fund its operations beyond 2026 and Legend Biotech's anticipated profitability in 2026; the progress of submissions with the FDA, the EMA and other regulatory authorities; expected results and timing of clinical trials; Legend Biotech's expectations on advancing its pipeline and product portfolio, and the potential benefits of Legend Biotech's product candidates, including the potential of LB2501, LB2505 and the reproducibility and durability of any favorable results initially seen in patients dosed to date in clinical trials. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Legend Biotech's expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including as a result of additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays, including requests for additional safety and/or efficacy data or analysis of data, or government regulation generally; unexpected delays as a result of actions undertaken, or failures to act, by our third party partners; uncertainties arising from challenges to Legend Biotech's patent or other proprietary intellectual property protection, including the uncertainties involved in the U.S. litigation process; competition in general; government, industry, and general product pricing and other political pressures; as well as the other factors discussed in the "Risk Factors" section of Legend Biotech's Annual Report on Form 20-F for the year ended December 31, 2025, filed with the Securities and Exchange Commission (SEC) on March 10, 2026 and Legend Biotech's other filings with the SEC.

Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this presentation as anticipated, believed, estimated or expected. Any forward-looking statements contained in this presentation speak only as of the date of this presentation. Legend Biotech specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

This presentation is for investor relations purposes only - Not for product promotional purposes

Non-IFRS financial metrics

This presentation refers to certain non-IFRS financial metrics.

We use Adjusted Net Income (Loss) and Adjusted Net Income (Loss) per Share (which we sometimes refer to as “Adjusted EPS”, or “ANI per Share”, respectively) as performance metrics. Adjusted Net Income (Loss) and ANI per Share are not defined under IFRS, are not a measure of operating income, operating performance, or liquidity presented in accordance with IFRS, and are subject to important limitations. Our use of Adjusted Net Income (Loss) has limitations as an analytical tool, and you should not consider it in isolation or as a substitute for analysis of our results as reported under IFRS. For example: (i) although depreciation and amortization are non-cash charges, the assets being depreciated and amortized may have to be replaced in the future, and Adjusted Net Income (Loss) does not reflect cash capital expenditure requirements for such replacements or for new capital expenditure requirements; (ii) Adjusted Net Income (Loss) excludes unrealized foreign exchange gain (loss); (iii) Adjusted Net Income (Loss) does not reflect changes in, or cash requirements for, our working capital needs; and (iv) Adjusted Net Income (Loss) excludes such as share based compensation expense, which has been, and will continue to be for the foreseeable future, a significant recurring expense for our business and an important part of our compensation strategy. Also, our definition of Adjusted Net Income (Loss) and Adjusted Net Income (Loss) per share may not be the same as similarly titled measures used by other companies.

However, we believe that providing information concerning Adjusted Net Income (Loss) and Adjusted Net Income (Loss) per Share enhances an investor’s understanding of our financial performance. We use Adjusted Net Income (Loss) as a performance metric that guides management in its operations of planning for the future of the business. We believe that Adjusted Net Income (Loss) provides a useful measure of our operation performance from a period to period by excluding certain items that we believe are not representative of our core business. We define Adjusted Net Income (Loss) as Net Income (Loss) adjusted for (1) non-cash items such as depreciation and amortization, share-based compensation, and impairment loss and (2) unrealized foreign exchange gain (loss). Adjusted Net Income (Loss) per Share is computed by dividing Adjusted Net Income (Loss) by the weighted average shares outstanding.

Reconciliations of Adjusted Net Income (Loss) and Adjusted Net Income (Loss) per Share to the most directly comparable IFRS measures are included at the end of this presentation.

This presentation is for investor relations purposes only - Not for product promotional purposes



Ingrid Zhang

Chief Executive Officer

This presentation is for investor relations purposes only - not for product promotional purposes

Q3 2026 Highlights & Recent Accomplishments



Q3 2026 Highlights


- Appointed Ingrid Zhang Chief Executive Officer
- CARVYKTI® Net Trade Sales grew 36% YoY[1] to **$710M**
  - 19% YoY growth in US
  - 86% YoY growth OUS
- CARVYKTI® is launched in 20 **global markets,** with 373[2] global activated CARVYKTI® treatment sites
- At IMS[3] 2026, announced five-year survival data from the CARTITUDE-2 Cohort A program in patients with multiple myeloma after one to three prior lines of therapy
- U.S. Food and Drug administration clearance of IND[4] for LB2501 for relapsed or refractory B-cell malignancies, including B-cell non-Hodgkin lymphoma


1. YoY: year over year 2. As of November 1, 2026. 3. Presented CARTITUDE 2 Cohort A results at 2026 International Myeloma Society (IMS) (Abstract #PA-288). 4. IND: investigational new drug application

This presentation is for investor relations purposes only - Not for product promotional purposes

Earlier Use of CARVYKTI May Increase 5-Year PFS[9] and OS[8] Based on Data Presented at IMS 2026

Numerically higher PFS and OS in 1-3 pLOT[7] (CARTITUDE-2 Cohort A) than in ≥3 pLOT (CARTITUDE-1)





	CART[3]-2 cohort A (N=20)	CART-1 (N=97)
Events, n (%)	10 (50.0)[a]	62 (63.9)
PFS, median (95% CI), mo	60.5 (12.9-NE)	33.3 (25.2-50.4)
5-y PFS rate (95% CI), %	54.2 (30.3-73.0)	33.7 (24.0-43.7)

	CART-2 cohort A (N=20)	CART-1 (N=97)
Events, n (%)	7 (35.0)[a]	47 (48.5)
OS, median (95% CI), mo	NR (21.9-NE)	60.7 (41.9-NE)
5-y OS rate (95% CI), %	69.2 (43.8-84.9)	51.3 (40.7-61.0)

95% of patients achieved CR[5]/sCR[10] as their best response

Three of the patients alive and progression-free at ≥5 years had bone marrow assessment (not required per protocol); all were MRD-negative at 10^{-6}

Median follow-up for CARTITUDE-2 Cohort A: 60.7 months

CARTITUDE-2 Cohort A (N=20), 1-3 prior LOT[6]

1/2 of Patients

treated with a single cilta-cel infusion remained alive and progression-free at **≥5 years without further anti-myeloma treatment**

CARTITUDE-1* (N=97), ≥3 prior LOT

1/3 of Patients

were treatment- and progression-free for **≥5 years after a single infusion**. Of these, 12 with serial MRD[11] assessments at a single center were MRD- and imaging-negative, the first evidence that cilta-cel is **potentially curative in RRMM[1,2]**

**Median prior lines of therapy was 6 (range, 3-18)*

[a]In CART-2 cohort A, 1 PFS/OS event after 5 years was a death due to unrelated breast cancer without progression of myeloma.

1. Jagannath S, et al. Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma. Journal of Clinical Oncology. https://doi.org/10.1200/JCO-25-00760; 2) Cohen A, et al. IMS 2026. Abstract PA-288. 2. RRMM: relapse refractory multiple myeloma. 3. CART: CARTITUDE. 4. cilta-cel: ciltacabtagene autoleucel. 5. CR: complete response. 6. LOT: line(s) of therapy. 7. pLOT: prior line(s) of therapy. 8. OS: overall survival. 9. PFS: progression-free survival. 10. sCR: stringent CR. 11. MRD: measurable residual disease

This presentation is for investor relations purposes only - Not for product promotional purposes

Advancing a Robust, Differentiated Cell Therapy Pipeline

Program	Target	Indication	Pre-Clinical	Phase I	Phase II	Phase III	NDA	Current Status	Partner
CARVYKTI®: BCMA-directed Autologous Therapy									
CARVYKTI®	BCMA	NDMM (Front-line) (Transplant Not Intended) (CARTITUDE-5)[1]		Multi-Regional Clinical Trial				*Patient follow-up*	Johnson&Johnson
		NDMM (Front-line, Transplant Eligible) (CARTITUDE-6)[1]		Multi-Regional Clinical Trial				*Patient follow-up*	
		NDMM (Front-line, Transplant Not Intended) (CARTITUDE-10)[1]		Multi-Regional Single Arm Trial				*Enrolling*	
Autologous Therapies									
LB1908	Claudin 18.2	Relapsed/Refractory Gastric & Pancreatic Cancers[3]		US IND				*Met primary endpoint, patient follow-up*	
LB2102	DLL3	2L+ Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma [3][4]		US IND				*Met primary endpoint, patient follow-up*	NOVARTIS
LB2401	GPRC5D	Relapsed/Refractory Multiple Myeloma[2]						*Patient follow-up*	
LB2402	CD19 x GPRC5D	Relapsed/Refractory Multiple Myeloma[2]						*Patient follow-up*	
LB2403	GPRC5D (FAST CAR)	Relapsed/Refractory Multiple Myeloma[2]						*Patient follow-up*	
LB2502	FcRH5 (FAST CAR)	Relapsed/Refractory Multiple Myeloma[2]						*Enrolling*	
Allogeneic Therapies									
LB2404D	CD19 x CD70 (CAR-γδ T)	Relapsed/Refractory Autoimmune Diseases[2]						*Enrolling*	
LB2405	CD19 x BCMA (CAR-NK)	Relapsed/Refractory Autoimmune Diseases[2]						*Enrolling*	
LB2302	CD20 (CAR-αβ T)	Relapsed/Refractory B-cell Non-Hodgkin Lymphoma[2]						*Enrolling*	
LB2303	CD19 x CD20 (CAR-γδ T)	Relapsed/Refractory B-cell Non-Hodgkin Lymphoma[2]						*Enrolling*	
LB2406	CD19 x CD20 (CAR-γδ T)	Relapsed/Refractory B-cell Non-Hodgkin Lymphoma[2]						*Enrolling*	
In Vivo Therapies									
LB2501	CD19 x CD20	Relapsed/Refractory B-cell Non-Hodgkin Lymphoma[2]						*Enrolling*	
LB2503	GPRC5D	Relapsed/Refractory Multiple Myeloma[2]						*Enrolling*	
LB2505	BCMA	Relapsed/Refractory Multiple Myeloma[2][5]						*Initiating*	

Notes:
1. In collaboration with Janssen, Pharmaceutical Companies of Johnson & Johnson. NDMM = Newly Diagnosed Multiple Myeloma.
2. Phase 1 investigator-initiated trial in China
3. IND applications have been cleared by the United States FDA
4. Subject to an exclusive license agreement with Novartis Pharma AG. The safety and efficacy of the agents and/or uses under investigation have not been established. There is no assurance that the agents will receive health authority approval or become commercially available in any country for the uses being investigated. Additionally, as some programs are still confidential, certain candidates may not be included in this list
5. Subject to the terms of Legend Biotech's collaboration and license agreement with Johnson & Johnson

LEGEND BIOTECH



In Vivo Pipeline Programs

Leveraging Stand-Alone Cell Therapy Leadership in *In Vivo*

1

LB2501

- Encouraging clinical activity from IIT trial presented at 2026 EHA Congress
- Favorable safety profile with **100% ORR[1] and CR rate (8/8) at DL2[2]**, out of 19 patients across 3 dose levels with a median follow-up of 4.8 mo (ASH abstract)
- IND Cleared by US FDA for Phase I/II Trial in relapsed or refractory B-cell malignancies

2

LB2505

- Phase I IIT trial in China evaluating LB2505, an investigational BCMA[3]-targeted *in vivo* CAR-T therapy for multiple myeloma
- This program is subject to the terms of Legend's collaboration agreement with Johnson & Johnson

1. ORR: objective response rate
2. DL2: dose level 2
3. BCMA: B-cell maturation antigen

Well Positioned For Long-Term Growth

CARVYKTI® Profitable[1]

$710M
Q3 2026 CARVYKTI Net Trade Sales

~$853 Million
Cash Position[2]

14
Pipeline Programs

CAR-T Leadership in MM[3]

- CARVYKTI® is the top-selling CAR-T in a single quarter[4]
- >$5B peak annual sales potential[5]

Cell Therapy Innovation

- Advancing next generation cell therapy pipeline, with promising in vivo data presented at EHA 2026
- FDA clearance of IND for LB2501 received in October

Durable Global Business

- ~$853 Million in Cash, Cash Equivalents and Time Deposits[2]
- Expect to achieve company-wide profitability in 2026[6]

15,000 patients treated with CARVYKTI® [7]

1. Net Trade Sales - Cost of Good Sold - Operating Expenses = CARVYKTI Profit; 2. As of September 30, 2026; 3. MM = Multiple Myeloma; 4. For the quarter ended September 30, 2026; 5. Legend Biotech and Johson & Johnson Estimate; 6. Company-wide profit defined as Adjusted Net Income; 7. As of October 14, 2026

This presentation is for investor relations purposes only - Not for product promotional purposes




Alan Bash

President, CARVYKTI®

This presentation is for investor relations purposes only - not for product promotional purposes

CARVYKTI® Sales Highlights

Expanding market penetration and earlier-line adoption represent a substantial and durable growth opportunity



	YoY Growth[1]	QoQ Growth[2]
U.S.	19%	0%
OUS[3]	86%	29%
Global[4]	36%	8%


- U.S. Dynamics:
  - Continued uptake in earlier treatment lines
  - 160 ATCs[5] includes ~40% community hospitals
- OUS[3] QoQ growth of 29% primarily driven by:
  - New geographic launches, with uptake in 20 markets worldwide
  - CARVYKTI® now available in 213 treatment sites OUS

1. Q3 2026 vs Q3 2025; 2. Quarter over Quarter growth for Q3 2026 vs Q2 2026 ; 3. OUS – Outside U.S. 4. Includes a currency impact; 5. ATC – Authorized Treatment Centers

This presentation is for investor relations purposes only - Not for product promotional purposes

Strong Earlier Line Expansion Progress in the U.S.

50% of Apheresed Patients in the U.S. were 2L[1] - 3L[2] in Q3 2026



1. 2L: second line setting
2. 3L: third line setting

This presentation is for investor relations purposes only - Not for product promotional purposes

Updated NCCN Guidelines: Considerations for Myeloma Therapy



National Comprehensive Cancer Network (NCCN) Guidelines Update

- All Patients with Myeloma should be referred to a T-cell therapy capable center at the time of first relapse for consideration of available therapies
- When both BCMA CAR-T and TCE[1]s are viable options, current data suggest that CAR-T is preferred given the established efficacy of TCEs following CAR-T cell therapy failure
- Minimize prior BCMA directed therapies in patients planning to receive BCMA CAR-T cell therapy

Updated September 2026

Version 2.2027. ©2026 National Comprehensive Cancer network ® (NCCN®), All rights reserved. NCCN Guidelines®
1. TCE: T-cell engager

This presentation is for investor relations purposes only - Not for product promotional purposes



Carlos Santos


Chief Financial Officer

This presentation is for investor relations purposes only - not for product promotional purposes

Progress Towards Sustainable Profitability in 2026

Strong underlying demand growth, with Operating Margin improving from -142% in 2Q23 to 6%[1] in 3Q26





Revenue has scaled at a **CAGR of 64%** since 2Q23, with gradual gross margin improvements

CARVYKTI® franchise became profitable in 2025, expect company-wide profitability in 2026[2]

1. For Q3 2026 excludes the one-time share-based compensation credit of $24 million
2. Company-wide profitability defined as Adjusted Net Income

This presentation is for investor relations purposes only - Not for product promotional purposes

Q3 2026 Financial Highlights

$ in millions (except per share)	Q3 2026	Q3 2025	Change
Collaboration Revenue	353.2	261.8	*35%*
License & Other Revenue	6.3	10.6	*-41%*
Total Revenue	359.5	272.4	*32%*
Gross Margin on Net Product Sales	*58%*	*57%*	*1%*
Total Operating Expenses	165.1	200.4	*-18%*
R&D	95.3	113.2	*-16%*
SG&A	69.8	87.2	*-20%*
Operating Income (Loss)	46.8	(43.3)	*NMF[3]*
Income Tax Benefit (Expense)	2.3	(0.6)	*NMF*
Net Income (Loss)	51.7	(39.6)	*NMF*
ANI[1] (Loss)[2]	55.6	(18.7)	*NMF*
ANI (Loss)[2] Per Share – Basic	$0.14	$(0.05)	*NMF*
ANI (Loss) Per Share – Diluted	$0.14	$(0.05)	*NMF*

Driving Operating Leverage Over Time

- Significant revenue growth of **32% YoY**
- Gross margin improved to **58%**, mainly driven by improved labor utilization and OOS[4] improvement
- Lower R&D investment of **-16% YoY** primarily driven by BCMA[5] frontline clinical studies maturing
- SG&A investment decreased 20% YoY and includes a $24 million one-time credit related to share-based compensation. **Excluding the impact of the one-time credit, SG&A would have increased 8%.**
- Operating expenses declined -18% YoY**.** Excluding the impact of the one-time credit, **operating expenses would have declined 6%**.
- Operating margin of 13% vs. -16% in 3Q25. Excluding the impact of the one-time credit **operating margin would have been 6%.**
- ANI grew to **$55.6 million** due to sustained operating leverage

1. ANI: Adjusted Net Income. 2. Adjusted Net Loss and Adjusted Net Loss per Share (on basic and diluted shares basis) are non-IFRS measures. Reconciliations of Adjusted Net Loss and Adjusted Net Loss Per Share to the most directly comparable IFRS measures are included at the end of this presentation. The definitions of these non-IFRS measures are at the beginning of this presentation. 3. Not Meaningful. 4. OOS: Out of Spec. 5. BCMA – B-cell maturation antigen.

This presentation is for investor relations purposes only - Not for product promotional purposes

Expected Profitability and Strong Balance Sheet for Business Sustainability

2026 Goals

- ✓ 3/4 of CARVYKTI® orders from 2-4L
- ✓ IND clearance for LB2501
- ✓ Present *in vivo* data
- • Company-wide profitability expected in 2026[1]

Investment Priorities

- Advancing *in vivo* CAR-T pipeline programs
- Focused, synergistic business development
- Modest capital expenditures for ongoing manufacturing capacity expansion

Balance Sheet Strength

- ~$853 million in Cash, Cash Equivalents and Time Deposits as of September 30, 2026
- No long-term debt

1. Company-wide profitability defined as Adjusted Net Income

This presentation is for investor relations purposes only - Not for product promotional purposes

Q&A



Ingrid Zhang
Chief Executive Officer



Alan Bash
President, CARVYKTI®



Carlos Santos
Chief Financial Officer



Yuhong Qiu
Interim Head of R&D

This presentation is for investor relations purposes only - not for product promotional purposes

Thank you!

This presentation is for investor relations purposes only - Not for product promotional purposes

Reconciliation of IFRS to Non-IFRS Metrics

	Three months ended September 30,	
($ in millions, except per share data)	**2026**	**2025**
Net income (loss)	51.7	(39.6)
Depreciation and amortization	11.0	6.0
Share-based compensation	(9.6)	15.0
Impairment loss (included in other operating expense)	0	0
Unrealized foreign exchange loss/(gain) (included in Other income/(expense), net)	2.5	(0.1)
Adjusted net income (loss)	55.6	(18.7)
Adjusted net income (loss) per share:		
Adjusted net income (loss) per share – basic	0.14	(0.05)
Adjusted net income (loss) per share – diluted	0.14	(0.05)
Financials under IFRS		
Earnings (loss) per share – basic	0.13	(0.11)
Earnings (loss) per share – diluted	0.13	(0.11)

This presentation is for investor relations purposes only - Not for product promotional purposes

LEGEND BIOTECH